Genetic, biochemical, and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after the introduction of newborn screening in the Netherlands. Issue 4 (19th April 2022)

• Record Type: Journal Article
• Authors: Schwantje, Marit; Fuchs, Sabine A.; de Boer, Lonneke; Bosch, Annet M.; Cuppen, Inge; Dekkers, Eugenie; Derks, Terry G. J.; Ferdinandusse, Sacha; Ijlst, Lodewijk; Houtkooper, Riekelt H.; Maase, Rose; van der Pol, W. Ludo; de Vries, Maaike C.; Verschoof‐Puite, Rendelien K.; Wanders, Ronald J. A.; Williams, Monique; Wijburg, Frits; Visser, Gepke
• Is Part Of: Journal of inherited metabolic disease. Volume 45:Issue 4(2022)
• Page Start: 804
• Page End: 818
• Publication Date: 2022-04-19
• Subjects: LCHAD deficiency -- LCKAT deficiency -- long‐chain fatty acid oxidation -- mitochondrial trifunctional protein complex -- MTP deficiency -- newborn screening; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12502
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency (LCHADD) is included in many newborn screening (NBS) programs. Acylcarnitine‐based NBS for LCHADD not only identifies LCHADD, but also the other deficiencies of the mitochondrial trifunctional protein (MTP), a multi‐enzyme complex involved in long‐chain fatty acid β‐oxidation. Besides LCHAD, MTP harbors two additional enzyme activities: long‐chain enoyl‐CoA hydratase (LCEH) and long‐chain ketoacyl‐CoA thiolase (LCKAT). Deficiency of one or more MTP activities causes generalized MTP deficiency (MTPD), LCHADD, LCEH deficiency (not yet reported), or LCKAT deficiency (LCKATD). To gain insight in the outcomes of MTP‐deficient patients diagnosed after the introduction of NBS for LCHADD in the Netherlands, a retrospective evaluation of genetic, biochemical, and clinical characteristics of MTP‐deficient patients, identified since 2007, was carried out. Thirteen patients were identified: seven with LCHADD, five with MTPD, and one with LCKATD. All LCHADD patients (one missed by NBS, clinical diagnosis) and one MTPD patient (clinical diagnosis) were alive. Four MTPD patients and one LCKATD patient developed cardiomyopathy and died within 1 month and 13 months of life, respectively. Surviving patients did not develop symptomatic hypoglycemia, but experienced reversible cardiomyopathy and rhabdomyolysis. Five LCHADD patients developed subclinical neuropathy and/or retinopathy. In conclusion, patient outcomes were highly variable, stressing the need for accurate classification of and discrimination between the MTP deficiencies to improve insight in the yield of NBS for LCHADD. NBS allowed the prevention of symptomatic hypoglycemia, but current treatment options failed to treat cardiomyopathy and prevent long‐term complications. Moreover, milder patients, who might benefit from NBS, were missed due to normal acylcarnitine profiles.